Status:
UNKNOWN
Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients
Lead Sponsor:
Assiut University
Conditions:
Colorectal Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
* Evaluation Of Glypican 3 in serum of colorectal cancer patients . * Correlation between Glypican 3 and clinicopathological characteristics of colorectal cancer .
Detailed Description
Colorectal cancer (CRC) is the third most common malignancy and the fourth most prominent cause of cancer-related deaths worldwide. Also it is the 7th commonest cancer in Egypt, representing 3.47% of ...
Eligibility Criteria
Inclusion
- Patients with colorectal cancer and admitted to south egypt cancer institute .
Exclusion
- Other malignant diseases .
- Patients received chemotherapy for colorectal cancer .
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04728139
Start Date
March 1 2022
End Date
October 1 2024
Last Update
January 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.